Predictive Oncology is a leading brand in the field of oncology that offers innovative solutions for drug discovery and development. With the aim of revolutionizing the field of radiation oncology, they have formed strategic partnerships and collaborations with industry leaders. Their flagship product, PEDAL™, combines AI technology with their extensive biobank of over 150,000 tumor samples from 137 cancer types, allowing for optimized, high-confidence drug-response predictions.

PEDAL enables researchers and clinicians to introduce the human element into oncology drug development earlier, improving the agility and efficiency of the drug discovery process. By leveraging incomplete data and selecting the best new data needed to make drug response predictions, PEDAL increases the probability of success. Additionally, PEDAL allows for the repurposing of shelved and failed drug compounds through new evaluation in additional tumor types.

With their advanced AI machine-learning platform, CORE™, developed by top researchers at Carnegie Mellon University, Predictive Oncology is at the forefront of innovation in the oncology industry. Start a PEDAL pilot program today to experience the benefits of their cutting-edge technology